Enhancing the activity of platinum-based drugs by improved inhibitors of ERCC1-XPF-mediated DNA repair.

Gloria CinieroAhmed H ElmenoufyFrancesco GentileMichael WeinfeldMarco A DeriuFrederick G WestJack A TuszynskiCharles DumontetEmeline Cros-PerrialLars Petter Jordheim

Published in: Cancer chemotherapy and pharmacology (2021)

Our results confirm the feasibility of the approach of targeting the protein-protein interaction between ERCC1 and XPF to sensitize cancer cells to alkylating agents, thanks to the improved binding affinity of the newly synthesized compounds.

Keyphrases

dna repair
protein protein
dna damage
small molecule
dna damage response
cancer therapy
dna binding